# Hospital Universitario Ramón y Cajal

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/hospital-universitario-ramon-y-cajal/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 40.5 |
| Citations | 1,400,043 |
| City | Madrid |
| Country | ES |
| Description | Hospital Universitario Ramón y Cajal is a research organisation in Madrid, ES. OpenAlex records 25,439 works and 1,400,043 citations for it. 7,079 researchers list it as their most recent affiliation. |
| Homepage | https://www.comunidad.madrid/hospital/ramonycajal/ |
| OpenAlex ID | https://openalex.org/I4210161852 |
| Researchers | 7,079 |
| ROR ID | https://ror.org/050eq1942 |
| Type | healthcare |
| Works | 25,439 |

## University papers

- [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/)
- [Vascular dementia](https://scholariq.org/papers/vascular-dementia/)
- [An Updated Definition of Stroke for the 21st Century](https://scholariq.org/papers/an-updated-definition-of-stroke-for-the-21st-century/)
- [Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-patients-with-advanced-or-metastatic-ntrk-fusion-positive-solid/)
- [Sleep Apnea and Cardiovascular Disease](https://scholariq.org/papers/sleep-apnea-and-cardiovascular-disease/)
- [Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer](https://scholariq.org/papers/association-of-the-lung-immune-prognostic-index-with-immune-checkpoint-inhibitor/)
- [Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study](https://scholariq.org/papers/amivantamab-in-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/)
- [COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study](https://scholariq.org/papers/covid-19-in-patients-with-thoracic-malignancies-teravolt-first-results-of-an/)
- [Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers](https://scholariq.org/papers/trastuzumab-emtansine-t-dm1-in-patients-with-previously-treated-her2/)
- [Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study](https://scholariq.org/papers/treatment-characteristics-and-real-world-progression-free-survival-in-patients/)

## University top topics

Showing 8 of 25.

- [Antibiotic Resistance in Bacteria](https://scholariq.org/topics/antibiotic-resistance-in-bacteria/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Cardiac Valve Diseases and Treatments](https://scholariq.org/topics/cardiac-valve-diseases-and-treatments/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [HIV/AIDS drug development and treatment](https://scholariq.org/topics/hiv-aids-drug-development-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.